+385.7%
CMI vs MRNA
+554.4%
-168.7%
-44.1%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +1.2% | +5.4% | -4.2% | +1.1% |
| 7D | -0.7% | -1.1% | +0.4% | -0.7% |
| 30D | -12.4% | +126.1% | -138.5% | -16.3% |
| 3M | -14.8% | +190.0% | -204.8% | -20.0% |
| 6M | +0.8% | +157.2% | -156.4% | -4.9% |
| YTD | +10.2% | +388.2% | -378.0% | +0.3% |
| 1Y | +37.4% | +467.0% | -429.6% | +23.9% |
| 3Y | +153.3% | +36.1% | +117.2% | +136.9% |
| 5Y | +167.6% | -68.0% | +235.6% | +150.9% |
| All | +385.7% | +554.4% | -168.7% | +319.2% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling